Table 3 Disease status and proteinuria after RTX cycle.

From: Repetitive administration of rituximab can achieve and maintain clinical remission in patients with MCD or FSGS

Disease Status/Cycle

Overall

Second

>= Three

Before induction

NR

35 (81.4%)

9 (69.2%)

17 (100%)

PR

7 (16.3%)

4 (30.8%)

0 (0%)

CR

1 (2.3%)

0 (0)

0 (0%)

After 3 months

NR

2 (4.8%)

1 (7.7%)

1 (6.2%)

PR

14 (33.3%)

5 (38.5%)

3 (18.8%)

CR

26 (61.9%)

7 (53.8%)

12 (75.0%)

After 6 months

NR

1 (2.3%)

1 (7.7%)

0 (0%)

PR

11 (25.6%)

4 (30.8%)

3 (17.6%)

CR

31 (72.1%)

8 (61.5%)

14 (82.4%)

Proteinuria in mg/d or mg/g creatinine (median/IQR)

At induction

5073 (3508–77859)

4680 (1570–6684)

5862 (4483–11618)

After 3 months

270 (45–860)

212 (54–601)

200 (34–1654)

After 6 months

94 (31–360)

94 (83–270)

101 (32–323)

  1. CR complete remission, NR nephrotic-range, PR partial remission.